Pegvisomant in acromegaly: a multicenter real-life study in Argentina
Pegvisomant in acromegaly: a multicenter real-life study in Argentina
复制标题
DOI：
10.20945/2359-3997000000160
复制
发表时间：
2019-08-01
期刊：
影响因子：
--
通讯作者：
Guitelman, Mirtha
中科院分区：
文献类型：
--
作者：
Basavilbaso, Natalia Ximena Garcia;Ballarino, Maria Carolina;Guitelman, Mirtha
目的：描述pegvisomant （PEGV）的长期安全性和有效性，以及现实生活中肢端肥大症患者治疗反应的预测因素。研究对象和方法：我们回顾性回顾了阿根廷17个中心的肢端肥大症患者使用PEGV治疗的临床、激素和放射学资料。结果：75例肢端肥大症患者（年龄22-77岁，女性51例）经PEGV治疗长达118个月（中位27个月）。在PEGV术前，97.3%的患者接受过内科治疗、手术和/或放疗，2例患者既往未接受过治疗。当时，所有患者的IGF-1均高于正常上限（ULN）（平均2.4 × ULN +/- 0.98，范围1.25-7）。肢端肥大症诊断时84%表现为大腺瘤，PEGV前仅23.5%的患者肿瘤残留bb101cm，其余患者显示正常或小于1cm影像。疾病控制(IGF-1
Objective: To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. Subjects and methods: We retrospectively reviewed the clinical, hormonal and radiological data of acromegalic patients treated with PEGV in 17 Argentine centers. Results: Seventy-five patients (age range 22-77, 51 females) with acromegaly have been treated with PEGV for up to 118 months (median 27 months). Before PEGV, 97.3% of patients had been treated with medical therapy, surgery and/or radiotherapy, two patients had no previous treatment. At that time, all patients had an IGF-1 above the upper normal limit (ULN) (mean 2.4 x ULN +/- 0.98, range 1.25-7). At diagnosis of acromegaly 84% presented macroadenomas, prior to PEGV only 23,5% of patients remained with tumor remnant > 1 cm, the remaining showed normal or less than 1 cm images. Disease control (IGF-1